DERMACYTE
DEAD

Serial Number

79364279

Owner

ILC Therapeutics Ltd

Attorney

Brian M. Davis

Filing Date

Dec 22, 2022

Add to watchlist:

No watchlists yet
View on USPTO

DERMACYTE Trademark

Serial Number: 79364279

DERMACYTE is a trademark filed by ILC Therapeutics Ltd on December 22, 2022. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

ILC Therapeutics Ltd

Biocity Scotland,

Entity Type: 99

Trademark Details

Filing Date

December 22, 2022

Registration Date

Not Registered

Goods & Services

Pharmaceuticals, medical and veterinary preparations for the treatment of damaged skin and tissue; sanitary preparations for medical purposes; dietetic food and beverages adapted for medical or veterinary use, food for babies; dietary supplements for human beings and animals; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides; pharmaceutical, medical and veterinary preparations for prevention, diagnosis and treatment of diseases, autoimmune diseases, allergies, allergic diseases, skin diseases, dermatitis, psoriasis, pruritic conditions, viral infections, coronaviruses, and inflammatory diseases; pharmaceutical, medical and veterinary preparations for the treatment of infectious diseases and for use in oncology; pharmaceutical, medical and veterinary preparations containing alpha interferon for the prevention, diagnosis and treatment of diseases and disorders, namely, cancer, autoimmune diseases, allergies, allergic diseases, skin diseases, dermatitis, psoriasis, pruritic conditions, viral infections, coronaviruses and inflammatory diseases; pharmaceutical, medical and veterinary preparations containing alpha interferon for the prevention, diagnosis and treatment of diseases and disorders, namely, cancer, autoimmune diseases, allergies, allergic diseases, skin diseases, dermatitis, psoriasis, pruritic conditions, viral infections, coronaviruses and inflammatory diseases, for animals; pharmaceutical, medical and veterinary preparations for the treatment of dermatitis; drug delivery agents in the form of coatings for tablets that facilitate the delivery of pharmaceutical preparations; drugs for medical purposes, namely, pharmaceutical preparations for treating allergies; biological preparations for medical use for the treatment of cancer; biological reagents for medical use; biological tissue cultures for medical use; biochemical preparations for medical use for the treatment of autoimmune diseases; anti-virals; diagnostic preparations for medical and veterinary purposes; clinical veterinary diagnostic reagents; immunoassay reagents for medical use

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Jan 1, 2026 FINT
FINAL DISPOSITION NOTICE SENT TO IB
Dec 16, 2025 FICS
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Dec 16, 2025 FICR
NEW REPRESENTATIVE AT IB RECEIVED
Oct 24, 2025 NREP
ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Dec 16, 2024 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Dec 16, 2024 ABN2
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Aug 17, 2024 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jul 31, 2024 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Jul 31, 2024 OPNR
NOTIFICATION OF FINAL REFUSAL EMAILED
Jun 1, 2024 GNFN
FINAL REFUSAL E-MAILED
Jun 1, 2024 GNFR
FINAL REFUSAL WRITTEN
Jun 1, 2024 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 24, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 24, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 24, 2024 TROA
REFUSAL PROCESSED BY IB
Nov 13, 2023 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Oct 24, 2023 RFCS
REFUSAL PROCESSED BY MPU
Oct 24, 2023 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Oct 13, 2023 RFCR
NON-FINAL ACTION WRITTEN
Oct 12, 2023 CNRT
ASSIGNED TO EXAMINER
Sep 23, 2023 DOCK
APPLICATION FILING RECEIPT MAILED
Mar 7, 2023 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 3, 2023 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Mar 2, 2023 REPR